Epividian
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Epividian sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Epividian: 8 sponsored US clinical trials, 1 recruiting.
Epividian sponsors 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. The most-studied condition in this pipeline is Immunogenicity, Vaccine, with 1 trials.
Upper-quartile sponsor footprint
Epividian sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
Observational Pharmaco-Epidemiology Research & Analysis
NCT03813862
Hepatitis C Diagnosis to Treatment Management
NCT05725109
Hepatitis C Screening Alerts
NCT05710120
External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA
NCT05495204
Cabenuva Injection Tracking in CHORUS
NCT04863261
COVID-19 Quantitative Antibody Titers & Booster Vaccinations
NCT05104359
Epividian / AHF: Positive Pathways - HIV Retention in Care
NCT04147832
Charlotte Retention in Care Study
NCT03584048
Therapeutic Areas
What is open in the Epividian pipeline
1 recruiting of 8 indexed (13% open); 7 completed (88%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Immunogenicity, Vaccine (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Epividian: open-pipeline peers nationwide
Peers matched on 8 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
Epividian sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 13% open enrollment (± trial volume)
- Addario Lung Cancer Medical Institute · 13% recruiting · 8 trials
- American University · 13% recruiting · 16 trials
- Annexon · 13% recruiting · 8 trials
- Ansun Biopharma · 13% recruiting · 8 trials
Related
What to do with this Epividian page
8 registered trials is a research-attention snapshot, not an endorsement of Epividian or any single study.
- 1 of Epividian's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Immunogenicity, Vaccine is the condition Epividian studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Immunogenicity, Vaccine trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Epividian pipeline card: 8 registered trials from official public datasets.Report a data error.